How to Choose a Cefuroxime Axetil Dry Syrup Manufacturing Partner for Your Pharma Brand

For pharma brands building or expanding a paediatric antibiotic portfolio in India, cefuroxime axetil 125mg/5ml dry syrup is one of the most strategically valuable formulations to add. Second-generation cephalosporins are prescribed with increasing frequency by paediatricians as a step-up from amoxicillin and amoxicillin-clavulanate — particularly for resistant ear infections, tonsillitis, chest infections, and UTIs in children where first-line antibiotics have not achieved adequate results.

But the quality and reliability of your manufacturing partner determines whether your brand delivers on the clinical expectations that paediatricians and parents associate with this drug class. Here are five critical factors every pharma brand buyer must evaluate.

1. WHO-GMP Certification — The Non-Negotiable Starting Point

Any third-party manufacturer you evaluate for cefuroxime axetil dry syrup 125mg must hold a current, valid WHO-GMP certificate covering oral solid and dry syrup manufacturing. This is not simply a regulatory checkbox — it is the minimum infrastructure guarantee that the manufacturer operates validated processes, calibrated equipment, and documented quality systems at every stage of production.

For paediatric antibiotic formulations specifically, ask for the certificate's issue and expiry date and confirm it covers dry syrup filling in the scope. A WHO-GMP certificate covering only tablets or capsules is not relevant to your dry syrup requirement.

2. Humidity-Controlled Manufacturing Environment

Cefuroxime axetil is a moisture-sensitive second-generation cephalosporin. Like amoxicillin-clavulanate and other beta-lactam combinations, it undergoes degradation when exposed to humidity during powder blending, granulation, and filling. The manufacturing suite must maintain controlled relative humidity — typically below 40% RH — throughout these stages, with real-time environmental monitoring and documented humidity excursion management procedures.

Ask your prospective manufacturer: what is the validated humidity specification for their dry syrup manufacturing room, and can they provide batch manufacturing records showing this parameter was within specification for a representative batch? Manufacturers who cannot produce this data are not operating to the standard your brand requires.

3. Glass Bottle + WFI Format Capability

The clinical-grade packaging specification for paediatric cefuroxime dry syrup — a 30ml amber glass bottle with a separately packaged Water for Injection (WFI) ampoule — requires specific manufacturing line capabilities that not all dry syrup fillers possess.

Glass bottle filling requires different tooling from PET, vibration-dampened filling heads to prevent breakage, and validated cap torque and induction-seal specifications. WFI co-packing requires sourcing from a qualified pharmaceutical WFI supplier and managing the co-packing process within the same product release framework as the dry powder.

A manufacturer who offers only PET bottles without WFI cannot supply to the quality standard that hospital formularies and branded paediatric antibiotic prescribers increasingly expect. Confirm glass + WFI capability before shortlisting.

4. Dual-API HPLC Batch Release Testing

Cefuroxime axetil batch release must include HPLC-based assay of the active pharmaceutical ingredient against a validated reference standard. For paediatric formulations where dosing is weight-based and small children receive a proportionally significant dose per kilogram, API content accuracy across the full fill range (first dose to last dose per bottle) is clinically critical.

Request the Certificate of Analysis (CoA) format from your prospective manufacturer and confirm it includes: HPLC assay result as % of label claim, related substances (degradation product) limits and results, water content (Karl Fischer), pH of reconstituted suspension, and microbial limits. A CoA missing any of these is a quality management gap that your brand will own in the market.

5. Regulatory Documentation and Export Support

If your brand operates in regulated export markets — or plans to — your manufacturing partner must be able to provide the regulatory documentation package required for product registration: Drug Master File (DMF) references, stability data at ICH conditions (accelerated 40°C/75% RH and real-time 25°C/60% RH), process validation reports, and site master file (SMF).

For domestic Indian market supply, verify that the manufacturer can support Form 9 and Form 10 (manufacturing and sale licence) documentation for your brand's name and address on the label, and that their manufacturing licence scope explicitly includes the product category.

Making the Right Choice for Your Paediatric Portfolio

Choosing a manufacturing partner for a paediatric cephalosporin dry syrup is a decision that affects both your brand's clinical reputation and your regulatory standing. The five factors above — WHO-GMP certification, humidity-controlled manufacturing, glass + WFI capability, HPLC batch testing, and regulatory documentation support — are the minimum evaluation criteria for any B2B buyer serious about product quality in this category.

For a complete overview of the clinical indications, dosage framework, and patient-facing specifications for this formulation, the guide on cefuroxime axetil syrup uses for children on the Delwis Healthcare blog covers the full clinical picture paediatricians and brand teams need.

Delwis Healthcare manufactures cefuroxime axetil dry syrup 125mg in glass bottles with WFI at our WHO-GMP certified facility in Ahmedabad — with full HPLC batch release, humidity-controlled dry syrup suites, ICH stability programmes, and complete regulatory documentation support. Our syrup and oral liquid manufacturing range also includes amoxycillin and potassium clavulanate oral suspension and other paediatric antibiotic dry syrups in our pediatrics range — giving brand partners a single sourcing point for a complete paediatric antibiotic oral liquid portfolio.

This article is written for pharmaceutical industry professionals and B2B procurement teams. It is intended for informational purposes within the pharmaceutical manufacturing and sourcing context.